pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Monoclonal Antibody · news · pharmadog
← back to Monoclonal Antibody
News · Monoclonal Antibody
785
stories
Oct 6, 26
Lycia seeks IPO for antibody degraders as TRexBio, Retension set terms
endpoints
Oct 6, 26
BioSpace 40 Under 40 winners make their mark on biopharma
biospace
Oct 5, 26
2 Massachusetts biotechs call it quits
biospace
Oct 5, 26
Genmab details ovarian cancer data; Lilly's Jaypirca gets a label expansion
endpoints
Oct 5, 26
Genentech pens $1.27B deal to access Alector’s preclinical blood-brain barrier asset
biospace
Oct 5, 26
CSL strikes up to $1.6B deal with Alentis for autoimmune drug with broad potential
biospace
Oct 5, 26
Biogen’s big lupus bet gets boost from new durability data for skin disease
biospace
Oct 5, 26
STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market
stat
Oct 5, 26
Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots
fiercebiotech
Oct 5, 26
Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere
fiercebiotech
Oct 5, 26
Opinion: FDA must ensure American patients can access new and experimental drugs
biospace
Oct 2, 26
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
Oct 2, 26
Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestone
endpoints
Oct 2, 26
‘We’ve been taking our time’: Buzzy AI biotech Xaira reveals antibody platform, first taste of pipeline
fiercebiotech
Oct 2, 26
Immunotherapy startup Adecto blames ‘risk-averse funding environment’ for closing down
fiercebiotech
Oct 1, 26
Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEO
fiercebiotech
Oct 1, 26
Sanofi, Regeneron broaden alliance to find their next Dupixent
biopharma dive
Oct 1, 26
United Therapeutics' legal victory; BMS' Camzyos approved for kids
endpoints
Oct 1, 26
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
biospace
Oct 1, 26
Pfizer’s eczema drug clears skin in mid-stage trial
biopharma dive
Oct 1, 26
#EASD26: Regeneron's antibody helps patients regain muscle after stopping GLP-1 therapy
endpoints
Oct 1, 26
STAT+: Invivyd’s pursuit of a Covid vaccine alternative gets a lift, but an FDA hurdle may await
stat
Oct 1, 26
Sanofi builds on immunology alliance with Regeneron for $1B upfront
endpoints
Oct 1, 26
STAT+: Sanofi, Regeneron expand partnership after Dupixent success
stat
Oct 1, 26
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
fiercebiotech
Sep 30, 26
AbbVie's eczema drug shows benefit in Phase 2; BioMarin lays off 117
endpoints
Sep 30, 26
Merck’s anti-TL1A antibody secures a win in ph. 2 hidradenitis suppurativa trial
fiercebiotech
Sep 30, 26
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
biospace
Sep 30, 26
Connect’s Dupixent rival reduces COPD attacks by 85%, but misses a secondary goal
fiercebiotech
Sep 30, 26
Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody
fiercebiotech
← prev
page 9 of 27
next →